Michael Bassett - ImpediMed Sr Officer

All Insiders . USA . 
Stock . ImpediMed Limited . Stakeholders . Insider . Michael Bassett
IPDQF Stock  USD 0.05  0.00  0.00%   

Insider

Michael Bassett is Sr Officer of ImpediMed Limited
Phone61 7 3860 3700
Webhttps://www.impedimed.com

ImpediMed Management Efficiency

The company has return on total asset (ROA) of (0.2848) % which means that it has lost $0.2848 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5192) %, meaning that it generated substantial loss on money invested by shareholders. ImpediMed's management efficiency ratios could be used to measure how well ImpediMed manages its routine affairs as well as how well it operates its assets and liabilities.
ImpediMed Limited has accumulated 170 K in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. ImpediMed Limited has a current ratio of 6.31, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist ImpediMed until it has trouble settling it off, either with new capital or with free cash flow. So, ImpediMed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ImpediMed Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ImpediMed to invest in growth at high rates of return. When we think about ImpediMed's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Rajat MarwahAlgoma Steel Group
50
Seng TanCapitaLand Investment Limited
60
Serge MorozPennantPark Investment
N/A
Chai KohCapitaLand Investment Limited
N/A
Dana LoncarGakovicOld Republic International
N/A
W RogersInsteel Industries
74
Grace ChenCapitaLand Investment Limited
N/A
Michael MoracaAlgoma Steel Group
N/A
Jonathan ShafferPennantPark Investment
N/A
Byron AziziPennantPark Investment
N/A
Chee LeeCapitaLand Investment Limited
48
W GrayOld Republic International
53
Soon GohCapitaLand Investment Limited
48
Barbara AdachiOld Republic International
70
Cecilia LamannaTitan International
N/A
Loris MolinoAlgoma Steel Group
N/A
James YorkInsteel Industries
65
Shawn GaleyAlgoma Steel Group
N/A
Anthony EheliTitan International
46
Simon TreacyCapitaLand Investment Limited
54
Patrick CPACapitaLand Investment Limited
N/A
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia. Impedined operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 73 people. ImpediMed Limited [IPDQF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity-0.52
Return On Asset-0.28

ImpediMed Limited Leadership Team

Elected by the shareholders, the ImpediMed's board of directors comprises two types of representatives: ImpediMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImpediMed. The board's role is to monitor ImpediMed's management team and ensure that shareholders' interests are well served. ImpediMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImpediMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
David BS, Ex Director
Nancy Deisinger, VP HR
Timothy Cruickshank, Chief Officer
Michael Bassett, Sr Officer
Shashi Tripathi, CTO COO
Walton Taylor, Medical Director
Richard Valencia, MD CEO
AAICD ACIS, Company Sec
Dennis Schlaht, VP Technology
Thomas Schenk, Chief Officer
Catherine Kingsford, VP Affairs

ImpediMed Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ImpediMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.52
Return On Asset-0.28
Profit Margin(1.88) %
Operating Margin(2.00) %
Current Valuation81.27 M
Shares Outstanding1.79 B
Shares Owned By Insiders13.73 %
Shares Owned By Institutions14.96 %
Price To Earning(8.46) X
Price To Book2.74 X

Currently Active Assets on Macroaxis

VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
MSFTMicrosoft
GMGeneral Motors

Other Information on Investing in ImpediMed Pink Sheet

ImpediMed financial ratios help investors to determine whether ImpediMed Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImpediMed with respect to the benefits of owning ImpediMed security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY